Last reviewed · How we verify
Antiplatelet Drug (antiplatelet-drug)
Pfizer's antiplatelet drug, which operates within the mechanism of aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol, has been discontinued, leaving no current market presence. The drug's development did not progress to later phases, indicating a lack of differentiation in a crowded therapeutic area. The primary risk associated with this decision is the loss of potential revenue and market share in the antiplatelet segment, where competition remains intense.
At a glance
| Generic name | antiplatelet-drug |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Approved indications
Pipeline indications
- Ischemic Stroke — discontinued
Common side effects
Key clinical trials
- Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy (PHASE3)
- Polypill in Acute Coronary Syndrome (PHASE2)
- Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I) (NA)
- Anti-Platelets in Chronic Obstructive Pulmonary Disease (PHASE2)
- Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (PHASE3)
- Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI) (PHASE3)
- Highest Efficacy of Dual Antiplatelet Therapy After Carotid Artery Stenting in High Bleeding Risk Patients (NA)
- Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiplatelet Drug CI brief — competitive landscape report
- Antiplatelet Drug updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI